Last reviewed · How we verify
NCT06103318: ICOgnition
eHealth Interventions for Breast Cancer Cognitive Impairment
NA trial testing ICOgnition in Breast Cancer in 176 participants. Status unknown.
7 April 2025
Quick facts
| Lead sponsor | Institut Català d'Oncologia |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 176 |
| Start date | 14 March 2024 |
| Primary completion | 7 April 2025 |
| Estimated completion | 7 September 2025 |
Drugs / interventions tested
- ICOgnition
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Cognitive Dysfunction — all drugs for Cognitive Dysfunction →
Sponsor
Institut Català d'Oncologia — full company profile →
Who can join
Adults 18 to 65, female only, with Breast Cancer or Cognitive Dysfunction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study investigates the effectiveness of integrating a cognitive rehabilitation module into a digital psychosocial intervention for recently diagnosed breast cancer patients. The trial involves 176 participants, with one group receiving the ICOnnecta't program (stepped psychosocial intervention) and the other receiving ICOnnecta't with an additional cognitive stepped intervention called ICOgnition. ICOgnition has three levels of intervention including cognitive screening and monitoring, psychoeducation, and online cognitive training. Assessments of the study outcomes will be conducted at baseline, 3 months, 6 months, and 1 year, measuring cognitive functioning, emotional well-being, medication adherence, work functioning, and overall quality of life. The study aims to improve understanding of efficient ways to detect cognitive dysfunction in cancer patients and assess the benefits and feasibility of this early intervention for managing cognitive impairment in breast cancer patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cognitive-enhanced eHealth psychosocial stepped intervention for managing breast cancer-related cognitive impairment: Protocol for a randomized controlled trial.
Serra-Blasco M, Souto-Sampera A, Medina JC, Flix-Valle A, et al · · 2024 · cited 2× · PMID 39070895 · DOI 10.1177/20552076241257082
Verify or expand the search:
- PubMed search for NCT06103318
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Institut Català d'Oncologia trials
Trials by the same sponsor.
- NCT06932276 — Implementing an Adapted Smoke-free Homes Intervention in Spain · NA · recruiting
- NCT06646315 — Early Versus Standard Care in Cancer Patients in Phase 1 Clinical Trials · NA · completed
- NCT05362669 — SMS Messaging for Invitation in the Cervical Cancer Screening Programme · NA · unknown
- NCT04372459 — Online Psychosocial Cancer Screening, Monitoring and Stepped Treatment in Cancer Survivors · NA · completed
- NCT04343950 — SMS Messaging as a Tool to Improve Cancer Screening Programs · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06103318 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut Català d'Oncologia
- Last refreshed: 6 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06103318.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing